Introduction
============

For most patients with chronic obstructive pulmonary disease (COPD), exercise intolerance is the most distressing consequence of the disease. Exercise intolerance can be improved by training and rehabilitation, and these are frequently included in the treatment for patients with COPD.[@b1-copd-8-347]--[@b3-copd-8-347] Previously, most pulmonary rehabilitation (PR) programs focused on exercising the lower extremities. However, upper-extremity exercise is increasingly recognized as an important component of PR.[@b2-copd-8-347],[@b4-copd-8-347] To evaluate PR of the upper extremities, exact measurement of the upper-extremity exercise capacity and physical activities of daily living (ADLs) is necessary.

The 6-minute pegboard and ring test (6PBRT) was developed by Celli et al[@b5-copd-8-347] to test patients with COPD. Zhan et al[@b6-copd-8-347] showed that the 6PBRT is a reliable method for the assessment of unsupported upper-extremity exercise in patients with COPD. However, the characteristics of 6PBRT measurements have not been fully investigated. Furthermore, the exact relationship between the 6PBRT and upper-extremity ADL remains unclear. The purpose of this pilot study was to determine the characteristics of the 6PBRT and to evaluate the relationship between this test and upper-extremity ADL in patients with COPD.

Methods
=======

Twenty patients with COPD were recruited from our outpatient clinics from January 2010 to August 2011. The diagnostic criteria for COPD were: a forced expiratory volume in 1 second (FEV~1~); a forced vital capacity (FVC) ratio ,70%; and a predicted FEV~1~ ,80% after bronchodilator inhalation. All patients had clinical histories consistent with mild to very severe COPD (stage 1, four patients; stage 2, six patients; stage 3, nine patients; and stage 4, one patient), according to the Global Initiative for Chronic Obstructive Lung Disease classification.[@b7-copd-8-347] Patients in a clinically stable condition were included, whereas those with exacerbation, hospital admission in the preceding 3 months, unstable cardiovascular disease, or a rapidly declining clinical course were excluded. This study was approved by the Human Subjects Committee of the Tottori University. The aim of the study was fully explained to participants, and all gave informed consent.

Body height, body weight, pulmonary function, maximal inspiratory pressure (PI~max~), maximal expiratory pressure (PE~max~),[@b8-copd-8-347],[@b9-copd-8-347] and grip strength were measured on the same day as the 6PBRT was performed. Spirometry was performed using a portable spirometer (DISCOM-21; CHEST MI, Inc, Tokyo, Japan) according to the American Thoracic Society guidelines.[@b10-copd-8-347] The predicted values for spirometric variables were calculated according to the Japanese Respiratory Society guidelines.[@b11-copd-8-347] PI~max~ and PE~max~ were measured with a Vitalopower KH-101 (CHEST MI, Inc). PI~max~ was measured at residual volume, and PE~max~ was measured at total lung capacity (TLC). Grip strength was measured using a digital grip-strength meter (TKK5401; Takei Scientific Instruments Co, Ltd, Niigata City, Japan). The severity of breathlessness in daily life was evaluated within 1 month of performing the 6PBRT by using the Japanese version of the Medical Research Council dyspnea scale.[@b13-copd-8-347]

The 6PBRT was performed according to the method of Zhan et al,[@b6-copd-8-347] with a slight modification. Briefly, subjects were asked to move as many rings (each ring weighed 50 g; Zhan et al had used rings weighing half an ounce) as possible in 6 minutes, and the score was the number of rings moved during the 6-minute period. Pulse oxygen saturation was measured during the test by using a SpO~2~ monitor (WEC-7201; Nihon Kohden Corporation, Tokyo, Japan) attached to the patient's ear lobe. Scores for dyspnea were evaluated using a modified Borg scale (0--10)[@b13-copd-8-347] immediately after the test.

Upper-extremity ADLs were evaluated using a physical activity questionnaire and an accelerometer within 1 month of performing the 6PBRT. The Japanese version of the modified Pulmonary Functional Status and Dyspnea Questionnaire (PFSDQ-M)[@b14-copd-8-347],[@b15-copd-8-347] was used in this study. The PFSDQ-M comprises three domains: dyspnea with activity, fatigue with activity, and change in activity level. From the "change in activity level" domain, six upper extremity activity items were selected to subjectively evaluate activities using the upper extremities: (1) brushing hair; (2) raising arms above the head; (3) bathing; (4) washing hair; (5) putting on a shirt; and (6) preparing lunch. The patients reported changes in these items, assigning a score from 0--10 for each activity as follows: 0 (no change: performs the activity as he/she always has); 1--3 (slight change); 4--6 (moderate change); 7--9 (extreme change); and 10 (no longer performs that activity). The response scores were then totaled.

In this study, upper extremity ADLs were also objectively quantified using a wrist accelerometer (Actiwatch 2®; Philips Respironics Inc, Murrysville, PA, USA), which is an instrument sensitive to movement. The wrist accelerometer is 43 × 23 × 10 mm in size and weighs 16 g; it records and stores the time and the intensity of movements. This device only has one recording mode, ie, activity counts. Activity counts are collected when the accelerometer detects motion over 1-minute epochs. When increased activity occurs in 1 epoch, the number of counts increases. The accelerometer was worn on the wrist of the nondominant hand, which was established when the patient was at the hospital, and activity counts were measured 24 hours a day for 7 consecutive days. The average activity counts were collected.

Data analysis
-------------

Statistical analyses were performed using GraphPad Prism 4 statistical software (GraphPad Software, Inc, San Diego, CA, USA). The results are expressed as the mean ± standard deviation. Pearson product moment correlation coefficients were used to determine the correlation between 6PBRT scores and pulmonary function, PI~max~, PE~max~, grip strength, and Actiwatch 2® counts. Spearman rank correlation coefficients were used to determine the correlation between 6PBRT scores and PFSDQ-M subdomain scores. A *P*-value ,0.05 was considered statistically significant.

Results
=======

Patient characteristics
-----------------------

Patient characteristics are shown in [Table 1](#t1-copd-8-347){ref-type="table"}. The 6PBRT was performed by all patients, and an average of 274 ± 91 rings was moved in 6 minutes ([Table 2](#t2-copd-8-347){ref-type="table"}). The median PFSDQ-M subdomain score was 2: eight of 20 patients scored 0, three of 20 patients scored .18, and others scored 2--8.

Correlation between 6PBRT score and pulmonary function tests
------------------------------------------------------------

There was a positive correlation between 6PBRT score and inspiratory capacity (IC) (*r* = 0.71, *P* , 0.001), IC/TLC predicted (*r* = 0.68, *P* , 0.01), vital capacity (VC) (*r* = 0.52, *P* , 0.05), and FVC (*r* = 0.57, *P* , 0.01); however, there was no significant correlation between 6PBRT score and any other index of pulmonary function ([Table 3](#t3-copd-8-347){ref-type="table"}).

Correlation between 6PBRT score and upper-extremity physical ADLs
-----------------------------------------------------------------

There was a negative correlation between 6PBRT score and PFSDQ-M subdomain scores (ρ = --0.49, *P* , 0.05) and a positive correlation between 6PBRT score and Actiwatch 2® counts (*r* = 0.54, *P* , 0.05) ([Figure 1](#f1-copd-8-347){ref-type="fig"} and [Table 4](#t4-copd-8-347){ref-type="table"}).

Discussion
==========

Upper extremity training is now recognized as an important component in the PR of patients with COPD.[@b4-copd-8-347] However, there are no specific recommendations on how to objectively measure upper-extremity exercise capacity or ADL. The objectives of this pilot study were to determine the characteristics of the 6PBRT via pulmonary function tests and to evaluate whether the 6PBRT can be used to measure upper-extremity ADL in patients with COPD.

Significant relationships between 6PBRT score and VC, FVC, IC, and IC/TLC predicted (%) were found in our study. During the 6PBRT, patients raised their hands to shoulder level or higher to move the rings, and this arm elevation position is similar to unsupported upper-extremity exercise. Unsupported upper-extremity elevation increases functional residual capacity.[@b16-copd-8-347]--[@b18-copd-8-347] This is likely due to passive stretching of the thoracic muscles and expansion of the rib cage, which imposes a greater burden that must be overcome by the diaphragm. Therefore, during unsupported upper extremity exercise, VC and IC decrease significantly[@b18-copd-8-347] and ventilation increases, which is associated with dynamic hyperinflation in patients with COPD.[@b11-copd-8-347] On the basis of these data, we speculate that in patients with intrinsically low IC, a further decrease in IC was caused by arm elevation during the 6PBRT, which led to a reduction in arm exercise capacity (as measured by the 6PBRT score), possibly through severe dynamic hyperinflation. Therefore, patients with low IC may have low upper-extremity exercise capacities.

In this study, upper-extremity ADLs in patients with COPD were evaluated using two methods, the PFSDQ-M (a questionnaire on upper-extremity activities subdomain) and the wrist accelerometer (Actiwatch 2®), to objectively quantify the activities. The 6PBRT score had a negative correlation with the PFSDQ-M subdomain and a positive correlation with Actiwatch 2® counts. Because there were significant relationships between 6PBRT score and upper extremity function as measured by both the PFSDQ-M and Actiwatch 2® counts, the 6PBRT is considered valuable and relevant for assessing upper-extremity ADLs. The 6PBRT can be a predictive marker of upper-extremity ADLs in patients with COPD.

Our study had some limitations. First, whether the Acti-watch 2® can accurately record daily upper-extremity activities has not been studied; therefore, the Actiwatch 2® counts need to be balanced against the activity counts measured with the more precise body motion accelerometer. Second, the sample size was small; thus, additional large-scale investigations are needed to verify our findings. Third, the full PFSDQ-M can evaluate other domains such as dyspnea and fatigue; however, this study was focused only on change in upper-extremity activity level, because this study mainly focuses on upper-extremity ADLs.

Conclusion
==========

Our data showed that there were clear correlations between 6PBRT score and IC, IC/TLC predicted, and upper-extremity ADLs in patients with COPD. When considering PR to maintain or improve physical activities in patients with COPD, the 6PBRT can be used as a reference index or potential test of upper-extremity ADLs.
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###### 

Subject characteristics

  Variables (n = 20)             
  ------------------------------ --------------------------
  Males/females, n               18/2
  Age, years                     76 (59--85)
  BMI, kg/m^2^                   20.0 ± 3.3
  GOLD stage: (n)                1: 4 2: 6 3: 9 4: 1
  MRC dyspnea scale score: (n)   0: 3 1: 1 2: 5 3: 8 4: 3
  VC, L                          2.99 ± 0.7
  VC predicted, %                93.3 ± 9.1
  IC, L                          1.83 ± 0.5
  IC/TLC predicted, %            30 ± 8.0
  FVC, L                         2.80 ± 0.7
  FVC predicted, %               88.2 ± 17.5
  FEV~1~, L                      1.31 ± 0.6
  FEV~1~ predicted, %            51.0 ± 20.7
  FEV~1~/FVC                     45.7 ± 12.7
  PI~max~, cmH~2~O               48.5 ± 18.6
  PI~max~ predicted, %           77.9 ± 30.5
  PE~max~, cmH~2~O               77.4 ± 33.5
  PE~max~ predicted, %           88.1 ± 38.3
  Grip strength, kg              26.2 ± 5.6

**Note:** The values shown represent the mean ± standard deviation or median (range), unless otherwise indicated.

**Abbreviations:** n, number; BMI, body mass index; GOLD, global initiative for chronic Obstructive Lung Disease; MRC, Medical Research Council; VC, vital capacity; IC, inspiratory capacity; TLC, total lung capacity; FVC, forced vital capacity; FEV~1~, forced expiratory volume in 1 second; PI~max~, maximal inspiratory pressure; PE~max~, maximal expiratory pressure; L, lung.

###### 

6PBRT score and upper extremity physical activity

  6PBRT score                           274 ± 91                    
  ------------------------------------- --------------------------- --------------
  SpO~2~                                96 (93--98)                 95 (81--99)
  Borg scale                            --                          4 (0.5--7.0)
  Upper extremity physical activities                               
   Actiwatch 2® counts                  193 × 10^3^ ± 102 × 10^3^   
   PFSDQ-M subdomain score              2 (0--29)                   

**Note:** The values shown represent the mean ± standard deviation or median (range).

**Abbreviations:** 6PBRT, 6-minute pegboard and ring test; PFSDQ-M, modified Pulmonary Functional Status and Dyspnea Questionnaire.

###### 

Correlation between 6PBRT score and pulmonary function, PI~max~, PE~max~, and grip strength

                         r[\*](#tfn5-copd-8-347){ref-type="table-fn"}   *P*-value
  ---------------------- ---------------------------------------------- -----------
  VC, L                  0.52                                           \<0.05
  VC predicted, %        0.38                                           NS
  IC, L                  0.71                                           \<0.001
  IC/TLC predicted, %    0.68                                           \<0.01
  FVC, L                 0.57                                           \<0.01
  FVC predicted, %       0.43                                           NS
  FEV~1~, L              0.39                                           NS
  FEV~1~ predicted, %    0.31                                           NS
  FEV~1~/FVC             0.14                                           NS
  PI~max~, cmH~2~O       0.36                                           NS
  PI~max~ predicted, %   0.31                                           NS
  PE~max~, cmH~2~O       0.16                                           NS
  PE~max~ predicted, %   0.21                                           NS
  Grip strength, kg      0.24                                           NS

**Note:**

Pearson's product moment correlation coefficient.

**Abbreviations:** 6PBRT, 6-minute pegboard and ring test; PI~max~, maximal inspiratory pressure; PE~max~, maximal expiratory pressure; VC, vital capacity; NS, not significant; IC, inspiratory capacity; TLC, total lung capacity; FVC, forced vital capacity; FEV~1~, forced expiratory volume in 1 second; L, lung.

###### 

Correlation of 6PBRT score and upper extremity physical activity

                            ρ (*r*)                                            *P*-value
  ------------------------- -------------------------------------------------- -----------
  PFSDQ-M subdomain score   −0.49[\*](#tfn7-copd-8-347){ref-type="table-fn"}   \<0.05
  Actiwatch 2® counts       0.54[†](#tfn8-copd-8-347){ref-type="table-fn"}     \<0.05

**Notes:**

Spearman's rank correlation coefficient (ρ);

Pearson's product moment correlation coefficient (r).

**Abbreviations:** 6PBRT, 6-minute pegboard and ring test; PFSDQ-M, modified Pulmonary Functional Status and Dyspnea Questionnaire.
